Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
High-Purity Recombinant Human Albumin Preparation Method
Tonghua Anrate Biopharmaceutical Co., Ltd. has filed USPTO Patent Application US20260098079A1 for a method of preparing high-purity recombinant human albumin using medium-long-chain fatty acid ligands and ion exchange chromatography. The application discloses a process where oleic acid, myristic acid, sodium palmitate, and sodium stearate are combined with recombinant human albumin in defined molar ratios with poloxamer to achieve high stability and purity through sequential anion and/or cation chromatography to remove truncated and modified albumins.
Protein Crystallization Method, Multiple Protein Feeds
Protein Crystallization Method, Multiple Protein Feeds
Affinity Chromatography Column for Cell Binding
USPTO published patent application US20260098840A1 by TQ Therapeutics GmbH for a column design for affinity chromatography. The invention comprises a column body with a retention volume containing a stationary phase, open ends for cell addition/removal, and obstacles such as grids or pins. The application covers the column design, a system of columns, and methods for binding cells using the disclosed technology.
Compositions and Methods for Screening Mutations in Thyroid Cancer
The USPTO published patent application US20260098297A1 on April 9, 2026, disclosing methods for screening mutations in thyroid cancer to determine whether patients with indeterminate thyroid nodules should undergo diagnostic surgery. The application covers screening patient thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to thyroid cancer-related genes. Six inventors are named including Shih-Min Cheng, Joseph Catanese, and Andrew Grupe. Filing date was December 9, 2025.
Low Dose Psilocybin in Foodstuff and Microbes for Same
USPTO published patent application US20260098286A1 by ATX PHARMERS LLC covering engineered microbes transformed with psilocybin genes under weak or medium-level promoters to produce low levels of psilocybin, with applications in microdose and sub-microdose foodstuff production. No compliance obligations or deadlines are imposed by this publication.
Cre-Lox AAV Gene Therapy Reconstitution System for Large Gene Delivery
The USPTO published patent application US20260098279A1 for a Cre-Lox AAV gene therapy system enabling delivery of therapeutic genes up to 16kb using up to four adeno-associated virus vectors with sequence-specific recombination. The invention by inventor Seongjin Seo includes novel lox site embodiments for near-unidirectional recombination. Applications include treatment of genetic disorders such as IFT140-associated retinitis pigmentosa and other retinal degeneration conditions.
Cells, Organs with Modified Genes for Xenograft Tolerance
Cells, Organs with Modified Genes for Xenograft Tolerance
Olezarsen (Tryngolza) Approved for Familial Chylomicronemia Syndrome
The MHRA has approved olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome (FCS) in adults. The approval was granted on 10 April 2026 to Swedish Orphan Biovitrum AB (publ) via IRP Route B. In a study of 66 adults, patients treated with Tryngolza showed an average 32% reduction in triglycerides after 6 months, compared with a 12% average increase in the placebo group, with benefits maintained and further improved after one year.
Antibacterial Compositions with Avermectin and Melatonin for Demodex Blepharitis Treatment
USPTO published patent application US20260097059A1 covering pharmaceutical compositions for treating Demodex blepharitis. The compositions include avermectin compounds (such as ivermectin derivatives) and melatonin, with optional concentrations under 1 wt %. The application also discloses wipe devices incorporating these treatment compositions. Inventor Rolando Toyos filed the application on January 30, 2025, with publication on April 9, 2026.
SGLT-2 Inhibitor Pharmaceutical Composition for Diabetes Treatment
The USPTO published patent application US20260097058A1 for a pharmaceutical composition containing SGLT-2 inhibitors for treating diabetes mellitus, impaired glucose tolerance, hyperglycemia, and metabolic disorders. Inventors include Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, and Rolf Grempler. The application was filed on December 11, 2025.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
737 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.